AI tool could spare half of liver cancer patients from needless treatment
NCT ID NCT07495735
First seen Apr 01, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study looks back at data from 400 liver cancer patients to build an AI system that predicts how well they will respond to a standard treatment (atezolizumab plus bevacizumab). The goal is to identify which patients are likely to benefit before starting therapy, avoiding unnecessary side effects for those who won't. The AI uses CT scans and other medical information, offering a non-invasive alternative to traditional biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.